	HOME
	WHAT IS ULCERATIVE COLITIS?
	ABOUT APRISO
»	WORKING WITH YOUR DOCTOR DISCUSSION GUIDE SYMPTOM TRACKER
	LIVING WITH UC
	SIGN UP FOR UC INFORMATION
	SIGN UP FOR APRISO SAVINGS

PRESCRIBING INFORMATION

FOR HEALTHCARE PROFESSIONALS

Talking to Your Doctor

Bringing a more honest relationship with your doctor to life.

Not everyone is the same, and the symptoms of ulcerative colitis (UC) can range in serverity from person to person. The important symptoms are the ones that affect you. That's why we've developed this interactive, customized conversation starter. You can choose the topics that are relevant to you, and bring the questions to your appointments.

The topics are conversation starters and suggestions on how to develop a list of questions that are important to you when you go to see your doctor.

Remember, taking UC medications such as once-daily APRISO and working with your doctor might help you manage your UC symptoms with less stress and more ease — with the end result of staying in remission longer.

APRISO is a locally acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis in patients 18 years and older. APRISO is contraindicated in patients with hypersensitivity to salicylates or aminosalicylates (sulfasalazine) or to any of the components of APRISO capsules. It is recommended that patients have an evaluation of renal function prior to initiation of APRISO therapy and periodically while on therapy. Exercise caution when using APRISO in patients with known renal dysfunction or a history of renal disease. There have been reports of hepatic failure in patients with pre–existing liver disease who have been administered mesalamine. Caution should be exercised when administering APRISO to patients with liver disease. The recommended dose of APRISO is four 0.375–g capsules once daily in the morning (1.5 g/day) with or without food. Because dissolution of the coating of APRISO granules depends on pH, APRISO should not be coadministered with antacids. Patients with phenylketonuria should be aware that APRISO contains aspartame, equivalent to 2.24 mg of phenylalanine per day. In 2 well–controlled clinical trials, the most common treatment–related adverse events occurring in at least 3% of adult patients taking 1.5 g/day of APRISO were headache (11% vs 8% for placebo), diarrhea (8% vs 7% for placebo), upper abdominal pain (5% vs 3% for placebo), nausea (4% vs 3% for placebo), nasopharyngitis (4% vs 3% for placebo), influenza and influenza–like illness (4% vs 4% for placebo), and sinusitis (3% vs 3% for placebo).

For complete Prescribing Information, please click here.